For chronic weight management in adult patients with a BMI ≥30, or ≥27 with 1 or more weight-related comorbidities as an adjunct to a reduced-calorie diet and increased physical activity. Click for Limitations of Use.

Obesity Epidemic

Take a scientific approach to treating obesity

The pathophysiology of obesity:
See what’s happening inside the body.

The Other Side of Obesity

Energy expenditure, metabolic concerns, the GLP-1 hormone, genetics. These are factors beyond your patients’ control that could be contributing to—or causing—their condition.1-3

A deeper scientific approach to obesity can help you target some of the triggers within the body that lead to excess weight.


References: 1. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604. 2. Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2014;16:9-21. 3. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012;126(1):126-132. 

Watch how Saxenda® works in the body

Watch how Saxenda® simulates a physiological
regulator of appetite.

A Mechanism that Helps Regulate Appetite

GLP-1 is a physiological regulator of appetite and caloric intake. Saxenda®the only FDA-approved GLP-1 receptor agonist for chronic weight management in adultsis 97% similar to native GLP-1 (7-37). Like native GLP-1, Saxenda® activates areas of the brain involved in appetite regulation.a

aShown in animal models.

Saxenda® Mechanism of Action
Mechanism of Action

Watch a video highlighting the efficacy of Saxenda®

Weight loss with Saxenda®:
Review the data 

Results that Matter

In a 56-week study, the majority of patients who remained on Saxenda® achieved clinically meaningful weight loss—and kept the weight off.


Based on a 56-week study of 3,731 patients without type 2 diabetes and with a BMI ≥30 kg/m2, or ≥27 kg/m2 with at least 1 weight-related comorbidity, receiving a reduced-calorie diet (~500 kcal/day deficit) and physical activity counseling.

  • Of patients randomized to placebo, 34% lost ≥5% of their body weight, and 15% lost >10% of their body weight. Statistically significant vs placebo (P<0.0001).
  • Patients were treated with Saxenda® (n=2,487) or placebo (n=1,244). Mean baseline body weight was 233.9 lb and mean baseline BMI was 38.3 kg/m2

Register for the latest updates about Saxenda®, including specific formulary coverage as it becomes available.

Selected Important Safety Information

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

Indications and Usage

  • Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use

  • Saxenda® is not indicated for the treatment of type 2 diabetes
  • Saxenda® and Victoza® both contain the same active ingredient, liraglutide, and therefore should not be used together. Saxenda® should not be used in combination with any other GLP-1 receptor agonist
  • Saxenda® has not been studied in patients taking insulin. Saxenda® and insulin should not be used together
  • The effects of Saxenda® on cardiovascular morbidity and mortality have not been established
  • The safety and efficacy of Saxenda® in combination with other products for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
  • Saxenda® has not been studied in patients with a history of pancreatitis

Important Safety Information (cont'd)


Saxenda® is contraindicated in the following conditions:

  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

  • Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the product components

  • Pregnancy

Warnings and Precautions

  • Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated
  • Acute Pancreatitis: Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide. After initiation of Saxenda® observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, Saxenda® should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, Saxenda® should not be restarted
  • Acute Gallbladder Disease: Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Risk of Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy: When Saxenda® is used with an insulin secretagogue (eg, a sulfonylurea) serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia. Monitor blood glucose parameters prior to starting Saxenda® and during Saxenda® treatment in patients with type 2 diabetes mellitus
  • Heart Rate Increase: Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed with routine clinical monitoring in patients treated with Saxenda® compared to placebo in clinical trials. Heart rate should be monitored at regular intervals consistent with usual clinical practice. Patients should inform healthcare providers of palpitations or feelings of a racing heartbeat while at rest during Saxenda® treatment. For patients who experience a sustained increase in resting heart rate while taking Saxenda®, Saxenda® should be discontinued
  • Renal Impairment: In patients treated with GLP-1 receptor agonists, including Saxenda®, there have been reports of acute renal failure and worsening of chronic renal failure, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported during postmarketing use of liraglutide. If symptoms of hypersensitivity reactions occur, patients must stop taking Saxenda® and promptly seek medical advice
  • Suicidal Behavior and Ideation: In the Saxenda® clinical trials, 6 (0.2%) of 3,384 patients treated with Saxenda® and none of the 1,941 with placebo reported suicidal ideation; one of the patients treated with Saxenda® attempted suicide. Patients treated with Saxenda® should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Saxenda® in patients who experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation

Adverse Events

  • The most common adverse reactions, reported in ≥5% are: nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase

Drug Interactions

  • Oral Medications: Saxenda® causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®

Use in Specific Populations

  • Nursing mothers should either discontinue Saxenda® or discontinue nursing
  • Safety and effectiveness of Saxenda® have not been established in pediatric patients. Saxenda® is not recommended for use in pediatric patients
  • Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis

Please click here for Prescribing Information.